Integra LifeSciences posts mixed Q1, cuts EPS guidance for tariff impact

 Integra LifeSciences (Nasdaq: IART)

 shares took a hit before hours today on first-quarter results that came in mixed compared to the consensus forecast.

Shares of IART fell 11% to $14.99 apiece in pre-market trading today. The investor response was potentially related to slashed adjusted EPS guidance in response to the expected impact of tariffs.

Integra LifeSciences reaffirmed its 2025 revenue guidance range for between $1.65 billion and $1.715 billion. That represents growth between 2.4% and 6.5%. However, the company reduced its adjusted EPS guidance to a range between $2.19 and $2.29. This accounts for an estimated 22¢ per share impact from tariffs imposed by the Trump Administration.

For the quarter, the Princeton, New Jersey-based medtech company reported losses of $25.3 million. That equals 33¢ per share on sales of $382.65 million for the three months ended March 31, 2025.

Integra recorded a more than $20 million bottom-line slide on a sales increase of 3.7%.

Adjusted to exclude one-time items, earnings per share came in at 41¢. That fell 2¢ shy of expectations on Wall Street. Sales managed to top estimates, though, as experts forecast $381.2 million in revenue.

The company continues to grapple with an FDA warning letter outlining quality systems issues at three locations.

“We remain laser-focused on strengthening our quality systems, improving supply reliability, and driving operational excellence. There remains significant work ahead, but we are continuing to put the processes and people in place to execute on our comprehensive compliance master plan and build a foundation for sustainable performance,” said Mojdeh Poul, president and CEO. “As I reflect on my first quarter at Integra and continue spending time across our operations and with employees, I remain inspired by the deep commitment of our teams to our customers and patients. I am also encouraged by the positive feedback I consistently receive from customers about the impact of our solutions and the value of our portfolio. I’m equally optimistic about the long-term growth and earnings potential of our differentiated offerings.”

https://www.massdevice.com/integra-mixed-q1-2025-guidance-tariff/